Please upgrade your browser.
The European Commission has granted a conditional marketing authorisation for a GlaxoSmithKline drug that treats the most common form of kidney cancer.
The widely used cancer drug bevacizumab (Avastin) is associated with a more than fourfold increased risk of severe urinary protein loss, a new review finds.
Immatics announces Phase II Results with its Therapeutic Cancer Vaccine IMA901 in Patients with Advanced Renal Cell Carcinoma
Results of multi-center phase II trial highlight the promise of cancer vaccines in showing strong signal for improved survival with significant correlation of immune response and survival and excellent safety profile.
AVEO Pharmaceuticals Tivozanib Demonstrates Progression-Free Survival of 14.8 Months in Subgroup of Patients with Advanced Kidney Cancer; Extended Duration of Treatment Continues to Highlight Favorab
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced data from a subgroup analysis of a Phase 2 randomized discontinuation trial showing that the median progression-free survival (PFS) achieved by patients with advanced clear cell renal cell carcinoma (RCC) who had undergone a prior nephrectomy was 14.8 months.
Argos Therapeutics Presents Positive Phase 2 Data for Arcelis Dendritic Cell-based Immunotherapy in Advanced RCC at ASCO
Argos Therapeutics today announced the presentation of positive interim data from a Phase 2 trial that evaluated the clinical activity, safety and immune response of AGS-003 treatment, given in combination with sunitinib, in patients with newly diagnosed advanced renal cell carcinoma (RCC).
Secreted frizzled-related protein-5 is epigenetically downregulated and functions as a tumor suppressor in kidney cancer
Secreted frizzled-related protein-5 (sFRP-5) has been identified as 1 of the secreted antagonists that bind Wnt protein. However, the functional significance of sFRP-5 in renal cell cancer (RCC) has not been reported. We hypothesized that sFRP-5 may be epigenetically downregulated through DNA methylation and histone modification and function as a tumor suppressor gene in RCC. Using tissue microarray and real-time RT-PCR, we found that sFRP-5 was significantly downregulated in kidney cancer tissues and cell lines, respectively. DNA bisulfite sequencing of the sFRP-5 promoter region in RCC cell lines showed it to be densely methylated, whereas there was few promoter methylation in normal kidney.
The authors of this report identified 7 preoperative variables that permitted them to identify patients who were unlikely to benefit from CN.
Recently, combinations of VEGF-inhibiting approaches have been studied in an attempt to maximize VEGF blockade and extend the clinical benefit of these approaches. Sunitinib (Sutent; Pfizer Inc, New York, NY), a small-molecule tyrosine kinase inhibitor of a family of receptors including VEGF receptor and bevacizumab (Avastin; Genentech, South San Francisco, CA), a recombinant humanized monoclonal antibody that binds and neutralizes circulating VEGF, have been previously combined in two separate phase I trials. A phase I trial conducted exclusively in metastatic renal cell carcinoma (RCC) and with fixed bevacizumab dosing at 10 mg/kg intravenously every 2 weeks reported unacceptable toxicity, including thrombotic microangiopathy (TMA).
A randomized double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment-naive locally advanced or metastatic renal cell carcinoma
Angiogenesis inhibitors have demonstrated significant clinical efficacy in mRCC. Pazopanib and sunitinib are both oral tyrosine kinase inhibitors primarily of VEGFR (-1, -2, and -3), PDGFR (-a and -b) and c-Kit. Pazopanib has a more selective kinase specificity profile compared to sunitinib and has demonstrated low rates of fatigue, hand foot syndrome and mucositis/stomatitis. There is an ongoing phase III head to head study of pazopanib vs. sunitinib in treatment naïve mRCC patients (pts). The outcomes of cancer therapy are traditionally evaluated using RECIST response and survival criteria. There is increasing emphasis on assessment of health related quality of life (HRQoL) particularly relevant to tolerability of agents. However, HRQoL questionnaires might not reflect the pt preference. Studies have shown an association between toxicity/intolerability and a response on HRQoL, suggesting that pt preference is a legitimate and useful endpoint.
|NeonCRM by Neon One|